Review Article Open Access
Autoimmune Disease: Pathogenesis, Genetics, Immunotherapy, Microbial triggers, Prophylaxis
Duncan D. Adams*
Faculty of Medicine, University of Otago, Dunedin, New Zealand
*Corresponding author: Duncan D. Adams, Faculty of Medicine, University of Otago, Dunedin, New Zealand, Tel: 64-3-4877989; E-mail: @
Received: February 23, 2014; Accepted: March 8, 2014; Published: March 13, 2014
Citation: Adams DD (2014) Autoimmune disease: Pathogenesis, Genetics, Immunotherapy, Microbial triggers, Prophylaxis. SOJ Immunol 2(1): 1-9.
Abstract Top
Pasteur’s correct Germ Theory of Disease led to discovery of the Immunity System that exists for defence against diseases caused by bacterial or viral infections. In order to cope with the huge diversity of microbial infections, the immune system needs a flexibility of immune response. This is provided by use of semi-random somatic gene mutations in lymphocytes, the cells that recognise invading bacteria and viruses.
Burnet realised that this flexibility leads to development of the Forbidden Clones of lymphocytes that cause the autoimmune diseases by accidentally being reactive with a host antigen instead of a microbial one. Ebringer has recently discovered the microbial triggers of rheumatoid arthritis and ankylosing spondylitis and has determined the amino acid sequences of the antigens on them that trigger the related autoimmune diseases. This has explained how histocompatibility antigens can predispose to autoimmune diseases. The Salk and Sabin anterior poliomyelitis vaccines have prevented the leg paralyses of the polio epidemics. We postulate that these paralyses were rare autoimmune complications of virtually universal poliovirus infection. As autoimmune diseases are triggered by microbial infections, we suggest that the triggering bacteria or viruses be sought, so that prophylaxis of the autoimmune diseases can be achieved by vaccination against their triggering microbes.
Keywords: Forbidden clone theory; H gene theory; Microbial triggers of autoimmune diseases; Poliomyelitis vaccines; Prophylaxis of poliomyelitis paralyses; Prophylaxis of autoimmune diseases
Introduction Top
Endemic goitre and its conquest
In mountainous parts of the world, such as Switzerland, the Himalayas, the Andes and New Zealand, Goiter (an enlargement of the thyroid gland) is common. This was discovered to be due to shortage in the soil of the trace element iodine [1]. Surprisingly, Kelly et al. [2], London scientists recruited by the Chilean government discovered that iodine in soil does not come from the weathering of rock. Iodine is dissolved in the sea from which it vaporizes by oxidation to be deposited in soils by rain. From the soil, iodine is taken up by plants from where it comes to man, directly in vegetables and fruit or indirectly through meat animals. Iodine takes a long time to build up in soils to the levels we need for manufacture of sufficient thyroid hormone. Geologically old soils, like those of England and France and the Eastern United States, contain adequate iodine for human need but the new soils of Switzerland, the Himalayas, Chile and New Zealand, where there has been geologically recent up-thrust of mountains have not had time to accumulate adequate amounts of iodine to meet the needs for humans and other animals. This causes goitre, an enlargement of the thyroid gland, caused by increased secretion of thyroid stimulating hormone from the pituitary gland aimed at enabling an enlarged thyroid to obtain more iodine from the blood. In New Zealand, HD Purves [3], with brilliant studies, found that the amount of iodine needed to be added to the domestic salt was 1 part of potassium iodide per 20,000 parts of sodium chloride, 10 times more than the ineffectual level previously used. This abolished New Zealand’s endemic goitre [4].
As Professor of Public Health and Preventive Medicine at Otago Medical School, Charles Hercus followed classic academic practice in requiring his 5th year medical students to write a thesis, on any topic they chose, giving scope for expression of originality. Duncan Adams seized this opportunity to write a thesis on the aetiology of asthma, from which he himself had suffered severely, leading to an invitation by Sir Charles Hercus for him to join the research world via a Medical Research Council Fellowship. This led on to years of professional research and Directorship of the MRC Autoimmunity Research Unit (Figure 1).
Figure 1: Dr Duncan Adams, MD DSc FRACP. Selected by Sir Charles Hercus for professional research with a Medical Research Council Fellowship which led on to discovery of the thyroid stimulating autoantibodies with HD Purves, Directorship of the MRC Autoimmunity Research Unit, The H Gene Theory of Autoimmune disease and the autoimmune model of schizophrenia with JG Knight.
The long mysterious pathogenesis and genetics of the autoimmune diseases is now solved [4,5]. The key to the pathogenesis is Jerne’s selection theory of antibody formation [6], which led to Burnet’s clonal selection theory of acquired immunity [7] and his forbidden clone theory of autoimmune disease [8]. This states that somatic gene mutations in multiplying lymphocytes produce the appropriately-named Forbidden Clones that cause the autoimmune diseases by reacting with a host antigen instead of a microbial one. Figure 2 illustrates clonal selection by antigenic stimulation and clonal diversification by somatic mutations in lymphocyte V genes. After discovery that the thyroid gland over-activity of Graves’ disease is caused by auto-antibodies that react with the thyroid’s receptor for thyroid-stimulating hormone from the pituitary gland (Figure 2) study of the properties of these auto-antibodies confirmed the Forbidden Clone theory by showing that they originate from single lymphocytes and show fine variation from patient to patient indicative of the random element in the mutations that produced them [9].
Figure 2: The pathogenesis of Graves’ disease. Thyroid-stimulating autoantibodies (TSaab) from forbidden clones of immunocytes stimulate the thyroid cells, causing overproduction of thyroid hormones T4 and T3 and the manifestations of thyrotoxicosis. The thyrotroph cells of the anterior pituitary are inhibited by the high blood thyroid hormone level, so TSH secretion ceases and response to TRH is absent. Some variants of TSaab react with receptors on fat cells in the orbit to cause exophthalmos from orbital adipocyte proliferation, demonstrated by Rundle and Pochin [9,57].
Classification of immune reactions causing disease
This is shown in (Table 1), where allergy and anaphylaxis and serum sickness are distinguished from the two types of autoimmunity, that caused by B cell forbidden clones and that caused by T cell forbidden clones.

Type I. Allergy and Anaphylaxis.

Gut worm-defence mechanism reacting to non-worm antigens [10,11].

Fault: a B lymphocyte IgE clone reactive with an allergen.

e.g. hay fever, anaphylaxis, gut allergy, skin allergy.

Type II.  Serum Sickness and Immune Complex Disease.

Fault: excessive quantity of antigen.

This swamps complement-neutralising mechanisms, leading to complement-mediated damage. Anti-microbial immune defense is designed to cope with picogram quantities of antigen, not milligrams of horse serum protein nor micrograms of released intra-cellular protein, such as nuclei [12,13].  

e.g. serum sickness following passive immunization against diphtheria toxin with horse serum, systemic lupus erythaematosus, lupus nephritis.  


Type III.  Autoimmunity.

Fault:  forbidden clones, which are anti-microbial lymphocyte clones with

accidental host-antigen specificity, arising from unlucky somatic mutations

in their lymphocyte V genes [9-14].

Type III B. Diseases caused by B lymphocyte forbidden clones:

e.g. Graves’ disease[15], myasthenia gravis [16], rheumatoid arthritis [17].

Type III T. Diseases caused by T lymphocyte forbidden clones:

e.g.  Diabetes Type 1 [18,19], diabetic retinopathy [20,21], experimental autoimmune encephalomyelitis[22] and presumptively  Addison’s disease, hypoparathyroidism, and other autoimmune diseases with specific parenchymal cell destruction[14].

Table 1: Classification of immune reactions causing disease.
Figure 3: Dr. Duncan Adams receiving a prize from the Chancellor of the University of Pisa for discovering the thyroid-stimulating autoantibodies that cause Graves’ disease.
Graves’ disease, a paradigm for autoimmune disease
In 1986, at the University of Pisa, Professor Aldo Pinchera et al. led an International Symposium on Thyroid Autoimmunity [23], at which Graves’ disease was described as a paradigm of autoimmune disease [15] and Duncan Adams (Figure 4) was awarded a Medal for Fundamental Contributions to Biomedical Science, namely discovery of the thyroid-stimulating auto-antibodies, first called the long-acting thyroid stimulator (LATS). This came from the experimental advantages provided by the presence of iodine in thyroid hormone, the hormone receptor nature of the auto-antigen and the control of thyroid activity by the pituitary gland.
Figure 4: Clonal selection by antigenic stimulation and clonal diversification by somatic mutation. Concept of Jerne [6] and Burnet [7].
Genetics Top
The familial aggregation
Studies of families, including twins, show that autoimmune diseases are weakly inherited, with disease specificity. The Mendelian pattern is that of multiple co-dominant genes with incomplete penetrance [14]. What genes are these? Before discussing this we need to describe the histocompatibility System.
The histocompatibility system
This system is essential for defense against virus infection, prevents allo-transplantation, and influences risk of autoimmune disease. Unlike the blood group antigens, A, B, O, on red blood cells, important for blood transfusions, the histocompatibility antigens are on the surface of all nucleated cells, including the white blood cells, the leucocytes, where they were discovered, and named by Dausset and Svejgard, the human leukocyte antigens (HLA) [24].
Involvement of the MHC in autoimmune disease
Vladutiu and Rose [25] discovered involvement in autoimmune disease of the major histocompatibility gene complex (MHC), which had been discovered in the field of surgical transplantation [26]. In man, a collection of genes on chromosome 6 code for peptides expressed on the surface of all nucleated cells. In the mouse a similar collection is on chromosome 17. Why does the MHC exist?
Functions of the MHC
First function: defense against virus disease: One of the classical experiments of recent times is that of Zinkernagel, et al. [27], who found that virus-infected cells extrude peptides from the virus into the Bjorkman Groove of their major histocompatibility antigens, this combined viral-histocompatibility antigen on the cell surface being the target for attack by the defensive cytotoxic T-cells. Adams [28] realized that the explosive speed of viral replication [29] necessitates this histocompatibility antigen involvement, which directs the cytotoxic T-cell attack on to the surface of the infected cell, destroying the virus factory, rather than ineffectively being muffled by the myriad numbers of free virions, as shown in (Table 2 [A,B,C]). This explains the Simonsen phenomenon [30], our having huge clones of cytotoxic T-cells reactive with allo-histocompatibility antigens, which our immune system mistakes for viral peptides on host histocompatibility antigens. The explosive speed of viral replication makes this mechanism necessary to prevent swift death of the virus-infected animal [28]. Polly Matzinger’s “Danger Theory” [31] is in full accord with Simonsen’s discovery that the immune system is far less concerned with things that are foreign than those that are dangerous.

1. The race between virus and cytotoxic T cell.

The  contestants

Replication time


Influenza virus

10 hours [29]

1,000 virions

Cytotoxic T- cell

18 hours

2 T cells

The race


T cells

Virion/T cell ratio

Day 1




Day 2

1 x 1,0002.4

106 x 21.3


Day 3

2.5 x 1014

6.3 x 106


Day 4

4 x 1021

1.6 x 107


The result:  the virus wins, the patient dies


Table 2: The Histocompatibility System exists for defence against virus infection.
(Adams DD. Lancet 1987; ii: 245-9.)
Second function: Imposition of polymorphism on the immune repertoire. This diversity usually enables some members of a population to survive an epidemic infection, preventing whole populations from being wiped out.
Third function: Imperfect defense against autoimmune disease. [4].
Fourth function: Provision of a gene haven for MHC Class-III gene products [4].
The H gene Theory of Inheritance of Autoimmune disease.
Building on the Bielschowsky’s discovery [32] of autoimmune anaemia in their NZB/BL strain of inbred mice, Howie and Helyer discovered that F1 hybrids of this strain with the healthy NZW strain unexpectedly develop the autoimmune kidney disease, lupus nephritis [33]. The occurrence of this disease in a hybrid, both of whose parents lack it, shows that at least one gene from each of the two parental strains causes the lupus nephritis. Back-cross and linkage studies showed that three genes contribute to the lupus nephritis [34], one from the NZB mice and two from the NZW mice. This has been confirmed, corrected and extended by Drake et al. [35] and Kono, et al. [36], using the wonderfully detailed microsatellite gene markers.
In all, Knight and Adams found four genes, with linkage information coding for autoimmune disease in mice [37]. None were the expected V genes, one was in the MHC and two appeared to be in the neighbourhood of the minor histocompatibility antigens, Hh and H-18 [37]. The linkage studies show that these are not the immunoglobulin V genes that were expected. Einstein [38] stated.
“The history of scientific and technical discovery teaches us that the human race is poor in independent thinking and creative imagination. Even when the external and scientific requirements for the birth of an idea have long been present, it generally needs an external stimulus to make it actually happen; man has, so to speak, to stumble right up against the thing before the idea comes.”
In an example of creative imagination, Adams and Knight put together the research fields of autoimmunity and transplantation, arriving at the H-Gene Theory of inheritance of autoimmune disease [39]. This states that histocompatibility antigen genes, major, minor and HY (the male sex antigen), together with the V (variable region) genes coding for antigen receptors on B and T-lymphocytes, are the germ-line immune response genes, the genes that influence the risk of autoimmune disease. The H-Gene Theory received general acceptance and wide admiration when delivered by John Knight to a distinguished audience at a Ciba Foundation Symposium in London in 1982 [40].
Immune Response Genes [14].
Table 3 lists the genes that govern the specificity of immune responses, indicating how they work. Section-A shows the germline variable region (V) genes, it provide the repertoire by coding for antigen receptors on B-cell and T-cell lymphocytes. For B-cell antigen receptors, the heavy chains are coded on chromosome14q, the κ light chains on chromosome 2p and the λ light chains on chromosome 22q. There are separate genes for the T-cell antigen receptors, which are of two types, αβ and γδ, coded for by genes on chromosomes 14q and 7q as shown in the Table 3. Section-B shows that new clones are added to the repertoire by somatic mutations in the V-genes of multiplying lymphocytes. Section-C shows that clones are subtracted from the repertoire by the H (histocompatibility antigen) genes which delete nascent complementary clones.




A. Providing the repertoire, the germline V genes



 a) Genes for B cell antigen receptors  

Heavy (V,D,J)



k light (V,J)



l light (V,J)


 b) Genes for T cell antigen receptors    

a (V,J)



b (V,D,J)



g (V,J)



d (V,D,J)


B. Adding new clones to the repertoire, somatic mutations in the

 V genes of multiplying lymphocytes.



C. Subtracting from the repertoire, the H (histocompatibility 

 Antigen) genes which delete nascent complementary clones.






Class I (A, B, C)        

a (very polymorphic)

6p Class II (DP, DQ, DR)

b-2 microglobulin   




b (very polymorphic)



A (less polymorphic)


Erythrocyte alloantigens        

A, B, O





The H-Y antigen, expressed in Bjorkman



Other minor H antigens expressed in Bjorkman



Table 3: Immune response genes [14]. The Germline H and V genes provide the germline predispositions to the autoimmune diseases and the random element of the somatic mutations in the lymphocyte V genes causes incomplete penetrance.
Τhe Class-I major histocompatibility antigens are on all nucleated cells but the Class II are only on B-lymphocytes and professional antigen presenting cells such as macrophage and dendritic cells.
Females have two X-chromosomes; males have an X-chromosome and a Y-chromosome which confers masculinity.
Aire (Autoimmune regulator) [41]
Mutations in the transcriptional regulator, Aire, cause APECED, a poly-glandular autoimmune disease. Animal models of APECED have revealed that Aire plays an important role in T cell tolerance induction in the thymus, mainly by promoting ectopic expression of a large repertoire of transcripts encoding proteins normally restricted to differentiated organs residing in the periphery. The absence of Aire results in impaired clonal deletion of self-reactive thymocytes, which escape into the periphery and attack a variety of organs.
The significance of this phenomenon for human autoimmune disease is most intriguing.
Microbial triggers
Autoimmune diseases are caused by malfunction of the immunity system, being consequences of infection by bacteria or viruses [41,42].
A. Rheumatic Carditis and Streptococci.
Before the advent of penicillin, rheumatic fever, with crippling or fatal lesions of the heart, was a frequent consequence of infection by β−haemolytic streptococci of Lancefield Group A. This was because of an antigenic similarity between a component of these streptococci and heart tissue, discovered by Kaplan and Meyeserian [43]. Today, with such infection therapeutically aborted by penicillin, rheumatic heart disease, once common, has become rare.
B. Glomerulonephritis and Streptococci.
Post-infective glomerulonephritis follows infection by Group-A streptococci of multiple M types. This disease is also less frequent due to use of antibiotics.
C. Reactive Arthritis.
This has been observed after enteric infection with Shigella, Salmonella, Yersinia, Compylobacter and genital infection with Neisseria gonorrhea.
D. Rheumatoid Arthritis (RA) and Proteus mirabilis [44].
Multiple studies over three decades have found high titres of antibodies against this bacterium in a total of 1375 RA patients, but not in other diseases or healthy controls in studies by independent groups in 15 different countries. There was no such elevation in antibodies against 27 other microbial agents. There is evidence that the upper urinary tract is the main site of Proteus infection in RA.
E. Ankylosing Spondylitis (AS) and Klebsiella [45].
In worldwide studies involving 1330 AS patients and 1191 healthy controls, the AS patients showed significantly increased antibody titres to Klebsiella. There is evidence that the gut is the main site of Klebsiella infection in AS.
F. Type 1 Diabetes and Coxsackie virus.
Richter and Horowitz [46] present the considerable evidence that Coxsackie viruses, especially B4, may trigger type1 diabetes, including the discovery that there are shared regions of homology between the Coxsackie virus protein PC-2 and the islet antigen GAD65.
G. Systemic Sclerosis and Infections.
Randone, et al. [47] describe the evidence suggesting that Parvovirus B19, Cytomegalovirus, Ebstein-Bar virus, Endogenous retrovirus, or Helicobacter pylori infection might trigger systemic sclerosis, where it has been postulated that fibroblast-stimulating forbidden clones, probably of B cell origin, are the immunological agent [8].
H. Schizophrenia and virus infection.
Acute schizophrenia has been observed to follow upper respiratory tract virus infection. Knight et al have assembled much evidence indicating that schizophrenia is an autoimmune disease caused by auto-antibodies that react with neuronal receptors influencing the limbic system [48-50]. Recently, Fabienne Brilot [51], a Paediatrician, has discovered dopamine-2 receptor antibodies in children with encephalitis. If these auto-antibodies are found in cases of acute schizophrenia, it will confirm the autoimmune basis of this disease.
Information from Sequencing Antigens on Triggering Bacteria
a. Basic books
Details of the development of the methods used for successful determination of the amino acid sequences of antigens on the rheumatoid arthritis-triggering bacteria, Proteus mirabilis are described in the book, “Rheumatoid arthritis and Proteus” by Ebringer [52] (Figure 5).
Figure 5: Professor Alan Ebringer, BSc, MD, FRCP, FRACP.
1. Discovered that Proteus mirabilis in the upper urinary tract triggers rheumatoid arthritis
2. Discovered that Klebsiella pneumoniae in the gut triggers ankylosing spondylitis
3. Confirmed the H Gene Theory by finding two antigens on Proteus, one resembling HLA-DR1/4 the predisposing HLA antigen, one resembling the autoantigen attacked.
4. Showed how HLA-B27 predisposes, 69-fold, to ankylosing spondylitis.
Similarly, the book “Ankylosing spondylitis and Klebsiella”, also by Ebringer [53], describes how the amino acid sequences of antigens on Klebsiella pneumoniae, that enormously increase the risk of ankylosing spondylitis, were determined, and how they exert their effect.
b. Confirmation of the H Gene theory
This research provides experimental confirmation, at the molecular level, of the H-Gene Theory of the inheritance of the autoimmune diseases, described above, in confirming the speculated presence of multiple antigens on triggering bacteria and alternative clonal development causing development of the forbidden clones that cause the associated autoimmune diseases.
c. How HLA-DR1/4 predisposes to Rheumatoid Arthritis [54]
Figure 6 shows space-filling models of the amino acid sequences of the histocompatibility antigen HLA-DR1/4 and the Proteus mirabilis haemolysin antigen. Close structural similarity is apparent. This means the immune tolerance imposed by the histocompatibility antigen will extend to this Proteus antigen, preventing immune reaction with it.
Figure 6: Molecular similarity between histocompatibility antigen HLA-DR1/4 and Proteus haemolysin, preventing immune reaction against this bacterial antigen.
Figure 7 shows space-filling models of the amino acid sequences of the Proteus mirabilis urease antigen and Type-11 collagen, an auto-antigen attacked in rheumatoid arthritis. The urease antigen is completely different from HLA-DR1-4, so will not be protected from immune reaction, being free to stimulate development of a forbidden clone reacting with the closely similar Type-11 collagen molecule, an auto-antigen attacked in rheumatoid arthritis.
Figure 7: Molecular similarity of Proteus urease with Type X1 collagen, an autoantigen attacked in rheumatoid arthritis.
d. How HLA-B27 predisposes to Ankylosing Spondylitis [55]
Figure 8 shows space-filling models of the amino acid sequences of the histocompatibility antigen HLA-B27 and two antigenic peptides on the bacterium Klebsiella pneumoniae. The Klebsiella nitrogenase antigen closely resembles HLA-B27, so will be covered by the tolerance induced by HLA-B27, but the bacterium’s pullanase peptide is different and able to stimulate development of a forbidden clone attacking the spine to cause ankylosing spondylitis.
Figure 8: Molecular similarity between HLA-B27 and the nitrogenase reductase peptide of Klebsiella pneumoniae, preventing immune reaction, and dissimilarity with the pullanase peptide (Pul D), of Klebsiella pneumoniae, allowing immune reactivity that can lead to development of the forbidden clones that cause ankylosing spondylitis, explaining the strong the strong genetic predisposition (69-fold) by HLA-B27 discovered by Schlosstein, Terasaki (1973).
Prophylaxis of autoimmune diseases
a. The Poliomyelitis virus epidemics
A New Zealand example occurred in 1938, reported in the press and observed by Adams trapped in a boarding school in Masterton. An epidemic of leg paralyses occurred in Christchurch and spread progressively north, from town to town, to Picton, Wellington, Featherston, then Carterton, the town next to Masterton, engendering great fear. Then the boy in the bed next to Adams complained of a stiff neck, was taken away and reported to have polio. Six months later he returned with a paralyzed leg. Adams and his schoolmates were all unaffected.
b. Paralysis a rare autoimmune complication of universal virus infection?
I postulate that the leg paralyses of poliomyelitis were a rare autoimmune complication of virtually universal virus infection, the paralyses probably caused by forbidden clones of cytotoxic T-cells which attacked anterior horn neurons in the spine, hence the Pathologists’ appropriate name, “acute anterior poliomyelitis.”
c. The lead in prophylaxis given by the polio vaccines
The Salk (killed) and Sabin (attenuated) polio vaccines have been brilliantly successful in preventing the polio leg paralyses. This exemplifies how autoimmune diseases in general, can be prevented by finding and vaccinating against their microbial triggers.
d. Finding microbial triggers
Ebringer has succeeded in this with rheumatoid arthritis and ankylosing spondylitis. He has pioneered this new field of medical research, developing a whole new technology that needs to be copied in other diseases, especially schizophrenia. Systematic studies of autoimmune diseases, with collaboration between clinicians and microbiologists are needed. The American Academy of Microbiology would be an ideal organization for doing the research needed to provide this urgently-needed knowledge.
Some disease associations are cross-tissue autoimmunity, for example the eye proptosis of Graves’ disease, caused by variants of the thyroid-stimulating auto-antibodies that react with receptors on orbital fat cells [56], and diabetic retinopathy [57], probably caused by destruction of retinal pericyte cells by antigenic variants of the T-cell forbidden clones that destroy the pancreatic islet β cells to cause Type-1 diabetes. Many autoimmune diseases, such as Graves’ disease, already have satisfactory therapy. Immunotherapy, by radiological or chemical immune ablation, with immune reconstitution by autologous bone marrow cells, pioneered by Tyndall [58], can be used to save the lives of patients with dangerous autoimmune diseases, such as systemic scleroderma [59].
Selective destruction of forbidden clones could be achieved by isolating their auto-antigen (such as the TSH receptor of Graves’ disease, cloned by Vassart and Dumont) [60] and attaching it to a cytotoxic moiety, such as bungarotoxin or 131I iodine (emitting short-range β particles), then administering the molecular complex intravenously to destroy the pathogenic clones of plasma cells.
When monoclonal antibody technology was discovered, it was mistakenly assumed that this would provide cures for the autoimmune diseases, a notion greatly encouraged by the drug companies. Struggling to help his patients get benefit from use of Rituximab, Dreyfus [61] envisages major progress from anti-viral therapies and ultimately virus vaccines. Prevention is better than cure, so finding and countering antigenic triggers of autoimmune diseases is the ideal. Recognition of the universality of microbial triggers of autoimmune diseases is a major advance, in showing how the diseases can be prevented by finding and vaccinating against their triggers. Ebringer has led the way by discovering two triggers and developing the technology for finding others.
  1. Hercus CE, Benson WN, Carter CL (1925) Endemic goitre in New Zealand and its relation to the soil iodine. J Hyg  24(3-4): 321-402.
  2. Kelly FC, Snedden WW (1960) Prevalence and geographical distribution of endemic goitre. WHO, Palais des Nations, Geneva, Switzerland, UK.
  3. Purves HD (1974-1975) Symposium. N Z Med J 80-81(529-532): 475, 548, 15, 61.
  4. Adams DD, Adams CD (2013) Autoimmune Disease. Springer, London.
  5. Adams DD, Knight JG, Ebringer A (2010) Autoimmune diseases: Solution of the environmental, immunological and genetic components with principles for immunotherapy and transplantation. Autoimmun Rev 9(8): 525-530.
  6. Jerne NK (1955) The natural-selection theory of antibody formation. Proc Natl Acad Sci USA 41(11): 849-857.
  7. Burnet FM (1959) The clonal selection theory of acquired immunity. Vanderbilt University Press, Cambridge, Nashville, USA.
  8. Burnet FM (1959) Auto-immune disease. BMJ 2(5153,5154): 645-650, 720-725.
  9. Adams DD (1980) Thyroid-stimulating autoantibodies. Vitam Horm 38: 119-203.
  10. Jarrett EE, Miller HR (1982) Production and activities of IgE in helminth infection. Prog Allergy 31: 178-233.
  11. Bell RG (1996) IgE, allergies and helminth parasites: a new perspective on an old conundrum. Immunol Cell Biol 74(4): 337-345.
  12. Adams DD (1983) Autoimmune mechanisms In: Davies TF (Ed.) Autoimmune Endocrine Disease. John Wiley & Sons, New York, USA, pp. 1-39.
  13. Adams DD (1982) Systemic lupus erythaematosus: a simple concept of the pathogenesis and its genetic basis. In: Dawkins RL, Christiansen FT, Zilko PJ (Ed.) Immunogenics in Rheumatology. Excerpta Medica Amsterdam, Netherlands, pp. 242-243.
  14. Adams DD, Knight JG (2003) Principles of autoimmune disease: pathogenesis, genetics and specific immunotherapy. J Clin Lab Immunol 52: 1-22.
  15. Adams DD, Knight A, Knight JG, Laing P (1987) Graves’ disease: a paradigm for autoimmunity. In: Pinchera A, Ingbar SH, McKenzie JM, Fenzi GF (Ed.) Thyroid Autoimmunity. Plenum, New York, USA, pp. 1-10.               
  16. Lindstrom J, Shelton D, Fujii Y (1988) Myasthenia gravis. Adv Immunol 42: 233-284.
  17. Ebringer A, Rashid T, Wilson C (2010) Rheumatoid arthritis, Proteus, anti-CCP antibodies and karl popper. Autoimmune Rev 9(4): 216-223.
  18. Sherwin RS (2000) Diabetes mellitus. In: Goldman L, Bennet JC (Ed.) Cecil Textbook of Medicine. (21stedn), Saunders, Philadelphia, USA, pp. 1263-1285.
  19. Sutherland DE, Goetz FC, Sibley RE (1989) Recurrence of disease in pancreas transplants. Diabetes 38(suppl 1): 85-87.
  20. Klintworth GK (1988) The eye. In: Rubin E, Farber JL (Ed.) Pathology (2ndedn.) Lippincott, Philadelphia, USA pp. 1456-1483.
  21. Adams DD (2008) Autoimmune destruction of pericytes as the cause of diabetic retinopathy. Clin Ophthalmol 2(2): 295-298.
  22. Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T cell lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11(3): 195-199.
  23. Pinchera A, Ingbar SH, McKenzie JM, Fenzi GF (1987) Thyroid Autoimmunity. Plenum Press, New York, USA.
  24. Dausset J, Svejgaard A (1977) HLA and disease. Williams & Wilkins Co, Copenhagen, Munksgaard, North and South America.
  25. Vladutiu AO, Rose NR (1971) Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type. Science 174(4014): 1137-1139.
  26. Auchincloss H, Sykes M, Sachs DH (1999) Transplantation Immunology. In: Paul WE (Ed.) Fundamental Immunology (4th edn) Lippincott-Raven, Philadelphia, USA, pp. 1175-1235.
  27. Zinkernagel RM, Doherty PC (1974) Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semi-allogeneic system. Nature 248(5450): 701-702.
  28. Adams DD (1987) Protection from autoimmune disease as the third function of the major histocompatibility gene complex. Lancet 2(8553): 245-249.
  29. Fenner F, White DO (1975) Medical Virology. (4th edn) Academic Press, London.
  30. Simonsen M (1970) On the nature and measurement of antigenic strength. Transplant Rev 3(1): 22-35.
  31. Matzinger P (2012) The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor. Expert Rev Clin Immunol 8(4): 311-317.
  32. Bielschowsky M, Helyer BJ, Howie JB (1953) Spontaneous haemolytic anaemia in mice of the NZB/BL strain. Proc Univ Otago Med Sch 37: 9-11.
  33. Howie JB, Helyer BJ (1968) The immunology and pathology of NZB mice. Adv Immunol 9: 215-266.
  34. Knight JG, Adams DD (1978) Three genes for lupus nephritis in NZB x NZW mice. J Exp Med 147(6): 1653-1660.
  35. Drake CG, Babcock SK, Palmer E, Kotzin BL (1994) Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW) F1 mice. Proc Natl Acad Sci USA 91(9): 4062-4066.
  36. Kono DH, Burlingame RW, Owen DG, Kuramochi A, Balderas RS et al (1994). Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 91(21): 10168-10172.
  37. Knight JG, Adams DD (1981) Genes determining autoimmune disease in New Zealand mice. J Clin Lab Immunol 5(3): 165-170.
  38. Einstein A (1934) Essays in Science. (1st edn) Philosophical Library, New York, USA, pp. 92.
  39. Adams DD, Knight JG (1980) H gene theory of inherited autoimmune disease. Lancet 1(8165): 396-398.
  40. Knight JG, Adams DD (1982) The genetic basis of autoimmune disease. In: David Evered, Julie Whelan (Ed.) Ciba Foundation Symposium 90 - Receptors, Antibodies and Disease, John Wiley & Sons, USA, pp. 35-56.
  41. Mathis D, Benoist C (2009) Aire. Annu Rev Immunol 27: 287-312.
  42. McKusick VA (1978) Mendelian Inheritance in Man. (5th edn), Johns Hopkins University Press, Baltimore, USA.
  43. Doria A, Sarzi-Puttini P, Shoenfeld Y (2008) Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev 8(1): 1-4.
  44. Doria A, Sampieri S, Sarzi-Puttini P (2008) Exploring the complex relationship between infection and autoimmunity. Autoimmun Rev 8(2): 89-91.
  45. Kaplan MH, Meyeserian M (1962) An immunological cross-reaction between Group A streptococcal cells and human heart tissue. The Lancet 279(7232): 706-710.
  46. Ebringer A, Rashid T, Wilson C, Ptazynska T, Fielder M (2006) Ankylosing spondylitis, HLA-B27 and Klebsiella pneumoniae – An overview proposed for early diagnosis and treatment. Curr Rheumatol Rev 2: 55-68.
  47. Richter MJ, Horowitz MS (2009) Coxsackievirus infection as an environmental factor in the etiology of  type1 diabetes. Autoimmun Rev 8(7): 611-615.
  48. Randone SB, Guiducci S, Cerinic MM (2008) Systemic sclerosis and infection. Autoimmun Rev 8(1): 36-40.
  49. Knight JG, Knight A, Pert CB (1987) Is schizophrenia a virally triggered antireceptor autoimmune disease? In: Helmchen H, Henn FA (Ed.) Biological Perspectives of Schizophrenia. John Wiley & Sons, New York, pp. 107–127.
  50. Laing P, Knight JG, Hill JM, Harris AG, Webster RG, et al. (1989) Influenza viruses induce autoantibodies to a brain-specific 37-kDa protein in rabbit. Proc Natl Acad Sci USA 86(6): 1998-2002.
  51. Knight JG, Menkies DB, Highton J, Adams DD (2007) Rationale for a trial of immuno-suppressive therapy in acute schizophrenia. Mol Psychiatry 12(5): 424-431.
  52. Dale RC, Merhev V, Pillai S, Wang D, Cantrill L, et al. (2012) Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135(11): 3453-3468.
  53. Ebringer A (2012) Rheumatoid arthritis and Proteus. Springer, London, UK, pp. 233.
  54. Ebringer A (2013) Ankylosing spondylitis and Klebsiella. Springer, Lonon, UK, pp 256.
  55. Wilson C, Ebringer A, Ahmadi K, Wrigglesworth J, Tiwana H, et al. (1995) Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. Ann Rheum Dis  54(3): 216-220.
  56. Ebringer A, Rashid T, Wilson C, Ptazynska T, Fielder M (2006) Ankylosing spondylitis, HLA-B27 and Klebsiella pneumoniae – An overview proposed for early diagnosis and treatment. Curr Rheumatol Rev 2: 55-68.
  57. Rundle F, Pochin E (1944) The orbital tissues in thyrotoxicosis: a quantitative analysis relating to exophthalmos. Clin Sci 5: 51-74.         
  58. Forge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, et al. (2004) Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis 63(8): 974-981.
  59. Englert H, Katelaris C, McGill N, Schrieber L, Moore J (2005) Grape-sultana sign represents a favourable response to aggressive treatment of early diffuse systemic scleroderma. Intern Med J 35(7): 436-437.
  60. Peret J, Ludgate M, Libert F, Gerard C, Dumont JE, et al. (1990) Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones. Biochem Biophys Res Commun 171(3): 1044-1050.
  61. Deyfus DH (2011) Autoimmune disease: A role for new anti-viral therapies. Autoimmun Rev 11(2): 88-97.
Listing : ICMJE   

Creative Commons License Open Access by Symbiosis is licensed under a Creative Commons Attribution 4.0 Unported License